Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
LipoScience IPO: Sale of 5 mil. shares in $80 mil. initial public offering is postponed Sept. 19. The maker of the NMR LipoProfile cardiovascular disease risk assessment test planned on pricing each share at $14-16 (1"The Gray Sheet" March 11, 2002, p. 18). The IPO, which originally had been targeted to raise $100 mil., was delayed following the stock market downturn the week of Sept. 16. The NMR LipoProfile is more expensive than traditional, standard-of-care cholesterol tests, which may have contributed to investor jitters...